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INTRODUCTION 
 Osteoarthritis (OA) represents a failure of the diarthrodial, synovial lined 
joint. Among the elderly, knee Osteoarthritis is the leading cause of chronic 
disability
1
. Because of the increased lifespan and obesity the prevalence of 
osteoarthritis is on the rise in Indian population. 
 Osteoarthritis is age related, affecting more than 80% of people over the 
age of 55.  OA in weight-bearing joints is strongly linked to body mass index. 
As life expectancy increases, and the rate of obesity reaches epidemic 
proportions, OA has become increasingly common. The pathogenesis involves 
an imbalance between normal cartilage derivative and repair mechanisms, which 
results in net cartilage loss, hypertrophy of bone, and osseous outgrowths called 
osteophytes. OA has a predilection for finger joints, knees, hips, shoulders, and 
the spine. Occurrence in an atypical joint, such as an elbow, can usually be 
traced to prior trauma, a congenital joint abnormality, underlying systemic 
disease, or a chronic crystalline arthropathy. The heterogeneity of OA arises 
from the many factors that can contribute to cartilage damage. 
 Symptomatic OA of the knee which is described as having pain during 
most days of a month along with radiologic evidence of arthritis has a 
prevalence of 22% to 39% in India
3, 4
. 
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 Osteoarthritis is a chronic disorder of synovial lined joints where there is 
progressive softening and disintegration of articular cartilage accompanied by 
new growth of cartilage and bone at the joint margins, cyst formation and 
sclerosis at subchondral regions of bone, mild synovitis and capsular fibrosis. 
 Osteoarthritis differs from simple wear and tear in that it is 
asymmetrically distributed, often associated with abnormal loading rather than 
frictional wear. It is not an inflammatory disorder although at times there are 
local signs of inflammation. In its most common form osteoarthritis is 
unaccompanied by any systemic illness. 
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RISK FACTORS 
1. AGE:    
 Age is the most powerful risk factor for osteoarthritis. The cartilage 
shows diminished cellularity, reduced proteoglycan concentration, loss of 
elasticity and a decrease in breaking strength with advancing years. 
2. INHERITANCE: 
 First degree relations had shown an increased incidence of osteoarthritis 
compared with controls. Mutations in COL2A1 genes have been associated with 
clinical phenotypes ranging from mild spondyloepiphyseal dysplasia to severe 
generalized osteoarthritis. 
3. TRAUMA: 
 Articular cartilage may be damaged by trauma or other inflammatory 
disorders. 
4. JOINT LOADING: 
 Increased mechanical stress in some part of the articular surface may lead 
on to development of osteoarthritis. 
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5. OBESITY 
 Obesity is one of the risk factor for both knee and hand osteoarthritis. 
People with higher ranges in body mass index are at increased risk of 
developing osteoarthritis. A weight loss of only 5 kg is associated with a 50% 
reduction in the odds of developing symptomatic knee osteoarthritis.  
 Three to six times body weight is transmitted across the knee during 
single-leg stance. Any increase in weight may be multiplied by this factor to 
reveal the excess force across the knee in overweight persons during walking.  
 Obesity is a well-recognized and potent risk factor for the development of 
knee OA and, less so, for hip OA. Obesity precedes the development of disease 
and is not just a consequence of the inactivity present in those with disease. It is 
a stronger risk factor for disease in women than in men, and in women, the 
relationship of weight to the risk of disease is linear, so that with each increase 
in weight, there is a commensurate increase in risk. Weight loss in women 
lowers the risk of developing symptomatic disease. Not only is obesity a risk 
factor for OA in weight-bearing joints, but obese persons having more severe 
symptoms from the disease. 
 Obesity's effect on the development and progression of disease is 
mediated mostly through the increased loading in weight-bearing joints that 
occurs in overweight persons. However, a modest association of obesity with an 
12 
 
increased risk of hand OA suggests that there may be a systemic metabolic 
factor circulating in obese persons that affects disease risk also. 
 Diagramatic representation of various risk factors culminating in 
susceptibility to osteoarthritis 
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6. FAILURE OF JOINT PROTECTIVE MECHANISMS   
Joint protectors are structures in and around the joint that include joint 
capsule, ligaments, afferent nerve fibers, muscle, and bone. Joint capsule and 
ligaments   limit excursion and fix range of motion, Synovial fluid reduces 
friction  induced cartilage wear by  providing a well lubricated gliding surface. 
This lubrication function depends on the molecule lubricin, a mucinous 
glycoprotein secreted by synovial fibroblasts. The concentration of synovial 
fibroblasts is found to diminish   in the face an injury to the joint or synovial 
inflammation. 
 Mechanoreceptor sensory afferent nerves are present over the ligaments, 
tendons and skin. These mechanoreceptors, throughout a joint's range of motion 
fire with different level of frequencies and provide feedback by way of the 
spinal cord to muscles and tendons. Thus these muscles and tendons act as 
optimal joint protectors, anticipating joint loading as they assume the right 
tension at appropriate points. 
Muscles and tendons that bridge the joint are key joint protectors. Their 
contractions at the appropriate time in joint movement provide the appropriate 
power and acceleration for the limb to accomplish its tasks. Focal stress across 
the joint is minimized by muscle contraction that decelerates the joint before 
impact and assures that when joint impact arrives, it is distributed broadly across 
the joint surface. 
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7. REPEATED USE OF JOINT 
 There are two categories of repetitive joint use, occupational use and 
leisure time physical activities. Workers performing repetitive tasks as part of 
their occupations for many years are at high risk of developing OA in the joints 
they use repeatedly. For example, farmers are at high risk for hip OA, and 
miners have high rates of OA in knees and spine, Even within a textile mill, 
women whose jobs required fine pincer grip [increasing the stress across the 
interphalangeal (IP) joints] had much more distal IP (DIP) joint OA than women 
whose jobs required repeated power grip, a motion that does not stress the DIP 
joints. Workers whose jobs require regular knee bending or lifting or carrying 
heavy loads have a high rate of knee OA. One reason why workers may get 
disease is that during long days at work, their muscles may gradually become 
exhausted, no longer serving as effective joint protectors. 
 While exercise is a major element of the treatment of OA, certain types of 
exercise may paradoxically increase the risk of disease. While recreational 
runners are not at increased risk of knee OA, studies suggest that they have a 
modest increased risk of disease in the hip.  
 However, persons who have already sustained major knee injuries are at 
increased risk of progressive knee OA as a consequence of running. Compared 
to non runners, elite runners (professional runners and those on Olympic teams) 
have high risks of both knee and hip OA.  
15 
 
 Given the widespread recommendation to adopt a healthier, more 
exercise-filled lifestyle; longitudinal epidemiologic studies of exercise contain 
cautionary notes. For example, women with increased levels of physical 
activity, either as teenagers or at age 50, had a higher risk of developing 
symptomatic hip disease later in life than women who were sedentary. Other 
athletic activities that pose high risks of joint injury, such as football, may 
thereby predispose to OA. 
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ARTICULAR CARTILAGE 
Articular cartilage is composed of two major macromolecular species  
(I)Proteoglycans:  
Proteoglycans are responsible for the compressive stiffness and the 
ability to withstand loads, of the tissues. 
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(II) Collagen:     
                   Collagen provides tensile strength and resistance to shear 
 Matrix metalloproteinases (MMP) such as collagenase, gelatinase and 
stromelysin are present in cartilage. These metalloproteinases can degrade 
components of the extra cellular matrix at neutral pH. Metalloproteinases are 
secreted in pro enzyme form and require proteolytic cleavage of n-terminal 
sequence for its activation. 
 MMP activity in the cartilage is basically a balance between proenzyme 
activation and inhibition of the active enzyme by tissue inhibitors. Aggrecan 
which is the major Proteoglycan in articular cartilage is degraded by 
aproteinase, named aggrecanase. 
 Interleukin -1 is a cytokine synthesized by synovial lining mononuclear 
cells and chondrocytes. Interleukin -1 stimulates the synthesis of proenzyme 
matrix metalloproteinases and tissue plasminogen activator.IL-1 suppresses PG 
synthesis by the chondrocyte, inhibiting matrix repair. 
 Human articular cartilage is primarily degraded by proteinase 
collagenase-3(MMP-13) and aggrecanase –1(ADAMTS4). Transcriptional 
activation by cytokines controls MMP-13 activity. Nuclear factor kappa –B and 
p38 mitogen activated protein kinase pathway, activates collagenase -3. 
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 Interest currently exists in the inhibition of cartilage matrix degradation 
by therapeutic agents that block the p38 dependent transcriptional activity of 
MMP-13 or control extracellular activation of the secreted form of ADAMTS4. 
 The balance of the system lies with inhibitors of matrix degrading 
enzymes, e.g., tissue inhibitor of metalloproteinase and plasminogen activator 
inhibitor-1, which are synthesized by the chondrocyte and limit the activity of 
MMPs and Plasminogen activator, respectively. 
 Chondrocytes induced by cytokines synthesize prostaglandin E2, bone 
morph genetic protein 2 (BMP-2) and nitric oxide, which together have complex 
effects on matrix synthesis and degradation. Nitric oxide enhances proteinase 
activity and inhibits aggrecan   synthesis.BMP-2 stimulates anabolic activity. 
  Healthy cartilages have a sluggish metabolism where synthesis and 
degradation of matrix is in balance. The cartilage in early OA or after an injury 
is highly metabolically active. The stimulated chondrocytes synthesize 
proenzymes and new matrix molecules, with those enzymes becoming activated 
in the matrix, causing release of degraded aggrecan and type 2 collagen  into 
cartilage and into the synovial fluid. OA cartilage is characterized by gradual 
depletion of aggrecan, an unfurling of the tightly woven collagen matrix, and 
loss of type 2 collagen. With these changes comes increasing vulnerability of 
cartilage, which loses its compressive stiffness. 
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HERITABILITY AND GENETICS 
  OA is a highly heritable disease, but its heritability varies by joint. Fifty 
percent of the hand and hip OA in the community is attributable to inheritance, 
i.e., to disease present in other members of the family. However, the heritable 
proportion of knee OA is at most 30%, with some studies suggesting no 
heritability at all. Whereas many people with OA have disease in multiple 
joints, this "generalized OA" phenotype is rarely inherited and is more often a 
consequence of aging. 
 Emerging evidence has identified genetic mutations that confer a high 
risk of OA, one of which is a polymorphism within the growth differentiation 
factor 5 genes. This polymorphism diminishes the quantity of GDF5, which 
normally has anabolic effects on the synthesis of cartilage matrix. 
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RISK FACTORS IN THE JOINT ENVIRONMENT 
 Some risk factors increase vulnerability of the joint through local effects 
on the joint environment. With changes in joint anatomy, load across the joint is 
no longer distributed evenly across the joint surface, showing an increase in 
focal stress.  
 Major injuries to a joint also can produce anatomic abnormalities that 
leave the joint susceptible to OA. For example, a fracture through the joint 
surface often causes OA in joints in which the disease is otherwise rare such as 
the ankle and the wrist. Avascular necrosis can lead to collapse of dead bone at 
the articular surface, producing anatomic irregularities and subsequent OA. 
 Tears of ligamentous and fibrocartilaginous structures that protect the 
joints, such as the anterior cruciate ligament and the meniscus in the knee and 
the labrum in the hip, increase joint susceptibility and can lead to premature OA. 
Meniscal tears increase with age and when chronic are often asymptomatic but 
lead to adjacent cartilage damage and accelerated osteoarthritis. Even injuries 
that do not produce diagnosed joint injuries may increase risk of OA, perhaps 
because the structural injury was not detected at the time. For example, in the 
Framingham study subjects, men with a history of major knee injury had a 3.5-
fold increased risk for subsequent knee OA knee. 
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Another source of anatomic abnormality is malalignment across the joint. 
This factor has been best studied in the knee, which is the fulcrum of the longest 
lever arm in the body. Varus (bowlegged) knees with OA are at exceedingly 
high risk of cartilage loss in the medial or inner compartment of the knee, 
whereas valgus (knock-kneed) malalignment predisposes to rapid cartilage loss 
in the lateral compartment. There is evidence that malalignment in the knee not 
only causes cartilage loss but leads to underlying bone damage, producing bone 
marrow lesions seen on MRI.  
 Malalignment in the knee often produces such a substantial increase in 
focal stress within the knee (as evidenced by its destructive effects on 
subchondral bone) that severely malaligned knees may be destined to progress 
regardless of the status of other risk factors.weakness in the quadriceps muscles 
bridging the knee increases the risk of the development of painful OA in the 
knee. 
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PATHOLOGY 
 The pathology of OA provides evidence of the involvement of many joint 
structures in disease. Cartilage initially shows surface fibrillation and 
irregularity. As disease progresses, focal erosions develop there, and these 
eventually extend down to the subjacent bone. With further progression, 
cartilage erosion down to bone expands to involve a larger proportion of the 
joint surface, even though OA remains a focal disease with non uniform loss of 
cartilage. 
 After an injury to cartilage, chondrocytes undergo mitosis and clustering. 
While the metabolic activity of these chondrocyte clusters is high, the net effect 
of this activity is to promote proteoglycan depletion in the matrix surrounding 
the chondrocytes. This is because the catabolic is greater than the synthetic 
activity. As disease develops, collagen matrix becomes damaged, the negative 
charges of proteoglycans get exposed, and cartilage swells from ionic attraction 
to water molecules. Because in damaged cartilage proteoglycans are no longer 
forced into close proximity, cartilage does not bounce back after loading as it 
did when healthy, and cartilage becomes vulnerable to further injury. 
Chondrocytes at the basal level of cartilage undergo apoptosis.  
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With loss of cartilage come alterations in subchondral bone. Stimulated 
by growth factors and cytokines, osteoclasts and osteoblasts in the subchondral 
bony plate, just underneath cartilage, become activated.  
 Bone formation produces a thickening and stiffness of the subchondral 
plate that occurs even before cartilage ulcerates. Trauma to bone during joint 
loading may be the primary factor driving this bone response, with healing 
from injury (including microcracks) producing stiffness. Small areas of 
osteonecrosis usually exist in joints with advanced disease. Bone death may 
also be caused by bone trauma with shearing of microvasculature, leading to a 
cut off of vascular supply to some bone areas. 
 At the margin of the joint, near areas of cartilage loss, osteophytes form. 
These starts as outgrowths of new cartilage and, with neurovascular invasion 
from the bone, this cartilage ossifies. Osteophytes are an important 
radiographic hallmark of OA. In malaligned joints, osteophytes grow larger on 
the side of the joint subject to most loading stress (e.g., in varus knees, 
osteophytes grow larger on the medial side). 
 The synovium produces lubricating fluids that minimize shear stress 
during motion. In healthy joints, the synovium consists of a single discontinuous 
layer filled with fat and containing two types of cells, macrophages and  
24 
 
 
fibroblasts, but in OA, it can sometimes become edematous and inflamed. There 
is a migration of macrophages from the periphery into the tissue, and cells lining 
the synovium proliferate. Enzymes secreted by the synovium digest cartilage 
matrix that has been sheared from the surface of the cartilage. 
 Additional pathologic changes occur in the capsule, which stretches, 
becomes edematous, and can become fibrotic. 
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SURGICAL ANATOMY 
 The knee joint is a synovial joint, the largest in the body. It is a modified 
Hinge joint in addition to flexion and extension a small amount of rotation of 
the leg is possible in the flexed position of the knee. It is a compound joint that 
includes two condoler joints between the femur and the tibia and a sellar 
(saddle) joint between the patella and the femur, the former being partly divided 
by menisci. The lateral and medial articular surfaces of the femur and tibia are 
asymmetrical. 
 The distal surface of the medial condyle of the femur is narrower and 
more curved than that of the lateral condyle. The lateral tibial articular surface is 
almost circular, the medial is oval with a longer anteroposterior axis, and these 
differences are reflected in the shapes of the menisci.  
 The articular surface of the patella is divided by a vertical ridge into a 
large lateral and a small medial surface; the latter is further subdivided by a faint 
vertical ridge into two smaller areas. The large lateral area articulates with the 
lateral condyle of the femur in extension and flexion. In extension the area next 
to it is in contact with the medial femoral condyle and the most medial area does 
not articulate with the femur. In flexion this surface is in contact with the medial 
condyle and the middle area is opposite the intercondylar notch of the femur. 
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LIGAMENTOUS SUPPORTS OF THE KNEE 
 Tibial collateral ligament is attached superiorly to medial femoral 
epicondyle and inferiorly attached to medial surface of tibia 
 Fibular collateral ligament is attached, proximally to lateral epicondyle 
and below to head of fibula covered by the tendon of biceps femoris. 
 Oblique popliteal ligament, expansion from the tendon of 
semimembranous blends with the capsule at the back of the joint and ascends 
laterally to the intercondylar fossa and lateral femoral condyle. The popliteal 
artery lies on it, and genicular vessels and nerves penetrate it. 
  Arcuate popliteal ligament is a Y-shaped thickening of posterior capsular 
fibres. The stem of the Y is attached to the head of the fibula. The medial limb 
arches over the tendon of popliteus to the posterior edge of the tibial 
intercondylar area. The lateral limb ascends to the lateral femoral condyle with 
the popliteus tendon. 
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INTRAARTICULAR STRUCTURES 
 The Principal Intra articular structures are the medial and lateral menisci 
and the anterior and posterior cruciate ligaments. 
 
 
 The ACL originates from the anterior tibial eminence and courses through 
the intercondylar notch to insert on the posteromedial aspect of the lateral 
femoral condyle. 
 The fascicles of the ACL can be grouped into anteromedial and 
posterolateral bands, named for the anatomical tibial insertion sites. The 
anteromedial band tightens with flexion, while the posterolateral band is taut in 
extension.  
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 The ACL serves as a primary restraint to anterior tibial translation. It is 
also an important secondary restraint to varus and valgus as well as tibial 
rotation. 
 Posterior cruciate ligament (PCL) takes origin from a depression between 
the posterior aspect of the two tibial plateaus. It inserts on to the lateral surface 
of the anterior portion of the medial femoral condyle.  
 Functionally, the PCL is composed of two bundles, anterolateral and 
posteromedial. The anterolateral band is tight in flexion and the posteromedial 
band tight in extension. 
 The PCL serves as the primary static restraint to posterior translation of 
the tibia.In addition, it is a secondary stabilizer to varus angulation and external 
tibial rotary displacement at 90° of knee flexion. 
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SURGICAL APPROACH 
 The surgical approach to the knee joint utilises a vertical anterior midline 
incision. On account of its variable course, the infrapatellar branch of the 
saphenous nerve may be at risk at the lower end of the incision. A medial skin 
flap is developed and the joint entered through an incision that divides the 
parapatellar retinaculum and extends above and below the patella as necessary.  
 The posterior approach to the knee joint utilises a S-shaped incision to 
avoid subsequent flexion contracture of the joint. The popliteal fascia is divided 
vertically and the interval between the tibial nerve and semimembranosus 
opened up by displacing the nerve and popliteal vessels laterally, and detaching 
the medial head of gastrocnemius from its femoral origin. 
An anterolateral portal is most commonly used for diagnostic knee 
arthroscopy and is sited just above the joint line lateral to the patellar tendon. A 
corresponding anteromedial portal is used for the insertion of instruments. 
Aspiration is usually carried out from the side at the upper lateral margin of the 
patella, the needle entering the suprapatellar bursa.  
 For injection the joint is entered at the lower border of the patella on 
either side of the patellar ligament. The needle tip must not damage the menisci 
or joint surfaces. 
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BIOMECHANICS OF THE KNEE
 
 The knee joint transmits loads, participates in kinematic function, aids in 
momentum conservation, and provides a force couple for purposeful activities 
involving the foot. 
 In addition to flexion and extension occurring in the sagittal plane, 
constant abduction and adduction are occurring in the coronal plane, and 
internal and external rotation are occurring in the transverse plane. 
 Flexion and extension do not occur about a fixed transverse axis of 
rotation, but rather about a constantly changing center of rotation, i.e. 
polycentric rotation
8
. When plotted, the path of this changing center of rotation 
describes a J-shaped curve about the femoral condyles. 
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 Flexion and extension of the knee are accomplished by both a 
rocking motion and a gliding motion between the femoral and tibial 
condyles. In a normal gait cycle, approximately 70° of flexion and 
extension occur during the swing phase, and 20° during the stance phase. 
Approximately 10° of abduction and adduction, and 10 to 15° of internal 
and external rotations occur during each gait cycle. 
 
 
 
Diagram showing Movement of femur—relative to the tibia during 
flexion showing contact points, generated by combination of rocking and 
gliding. 
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 Joint surfaces are subject to a loading force equal to three times the 
bodyweight in level walking. In climbing stairs, the force increases to four times 
the body weight. In a normally aligned knee, the weight bearing is shared across 
the medial and lateral tibial plateaus, 70% over medial and 30% over lateral. 
When malalignment exists, such as in varus or valgus deformity, a significant 
shift in the joint load to one side of the articulation occurs. 
 In a varus deformity almost 100% weight is borne by medial plateau. 
Corrective osteotomies about the knee attempt to reestablish a more normal 
weight bearing distribution across the joint surface of the knee. 
 The mechanical axis of the lower limb extends from the center of the 
femoral head to the center of the ankle joint, and should pass through or near the 
center of the knee in a normally aligned lower limb. Because the hips are more 
widely separated than the knee and ankle, this mechanical axis is in 3° of valgue 
from the true vertical axis of the body which extends from the center of gravity 
to the ground. 
 The anatomic axis of the femur (femoral shaft axis) is in approximately 6 
degrees of valgus from the vertical axis with variations according to body 
habitus. 
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Furthermore, the anatomic axis of the tibia is approximately 2 to 3° of 
varus from the mechanical axis by their measurement. The clinical implications 
of these facts are that when performing a total knee replacement, the femoral 
component should be placed in 9 ± 2° of valgus from the vertical axis, and the 
tibial component in 2 to 3° of varus. 
 The biomechanical functions of the patella allow for a wider distribution 
of forces on the distal femur. The patella prevents tendon-joint contact during 
flexion of the knee. It also effectively lengthens the lever arm of the quadriceps 
muscle through knee range of motion. 
 The menisci are important in reducing stress on the cartilage. Differential 
contributions of the medial and lateral menisci to load Transmission have   been 
shown. The load across the medial compartment is borne and the meniscus 
carries 70% of the load transmitted. 
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 Alterations in the vertical and transverse axes may occur with disruptions 
and derangements of the vertical axes of rotation shifts medially and vice versa. 
Because of the eccentricity of the femoral condyles the transverse axis of 
rotation constantly changes position (instant center of rotation) as the knee 
progresses from extension into flexion. 
Changes in the ―instant center of rotation‖ are often detectable 
kinematically and are responsible for many of the degenerative conditions about 
the knee joint. 
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CLINICAL FEATURES 
Joint pain of OA is often described as deep ache localized to the involved 
joint. The pain is aggravated by joint use and relieved by rest but as disease 
progresses, it may become persistent. Articular cartilage is aneural, joint pain in 
OA must arise from other structures 
Source Mechanism 
Synovium Inflammation 
Subchondral Bone 
Medullary Hypertension, 
Microfractures 
Osteophytes 
Stretching Of Periosteal Nerve 
Endings 
Ligaments Stretch 
Capsule Inflammation,Distension 
Muscle Spasm 
 
Physical examination: 
 Localized tenderness ,bony or soft tissue swelling 
 Bony crepitus 
 Joint effusion 
 Restriction of mobility 
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THE CARDINAL SIGNS OF OSTEOARTHRITIS 
 Narrowing of the ‗joint space‘ 
 Marginal osteophytes 
 Subchondral cysts 
 Bone remodeling 
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MANAGEMENT 
The initial conservative management includes: 
1. Obesity is a well-known risk factor for the development of osteoarthritis 
and weight loss definitely slows down the progression of disease. 
2. Avoidance of ground level activities reduces the mechanical stresses on 
the various compartments of knee and hence slows the progression of 
osteoarthritis. Avoidance of squatting, Indian toilet seat etc are strongly 
advised. 
3. Strengthening of quadriceps and hamstrings and proper muscle balancing 
around the knee have been found to reduce the pain and disability of the 
knee in OA.
8,9.
There has been evidence from large randomized controlled 
trials that joint specific exercises reduce pain and improve function in 
knees as do the aerobic exercise regimens. 
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NSAIDs:  
 They are the most commonly used drugs for OA knee for reducing the 
pain and inflammation associated with the knee. Unfortunately their continuous 
use is associated with serious side effects. Paracetamol should be considered the 
drug of first choice as it is comparatively much safer. Gastritis, peptic ulcers and 
peptic ulcer rupture are well known complications of these NSAIDs. Besides, 
chronic renal failure is one of the most serious consequences of prolonged use. 
 Symptomatic Slow Acting Drugs for OA (SYSADOA) (glucosamine 
sulphate, chondroitin sulphate, diacerein, and hyaluronic acid). 
  There is evidence to suggest that these drugs may possess structural 
modification properties, but more methodological studies are required to prove 
the same. 
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Arthroscopic debridement: 
  Recent advances in instrumentation and a growing understanding of the 
pathophysiology of osteoarthritis have led to increased use of arthroscopy for 
the management of degenerative arthritis of the knee. Immediate symptomatic 
relief can be expected in almost all the patients. In properly selected patients 
arthroscopic debridement can provide long-lasting pain relief, improvement in 
quality of life, delay and in a few cases even obviate the need of reconstructive 
procedures. 
Proximal/High Tibial Osteotomy (HTO):  
 Proximal tibial osteotomy is a well established procedure for the last     40 
years known to decrease pain and improve functional results in 
unicompartmental knee arthritis. 
   HTO is indicated in patients with pain and disability resulting from 
osteoarthritis with weight bearing roentgenograms showing degenerative 
changes confined to one compartment with a corresponding varus or valgus 
deformity with the patient possessing sufficient muscle strength and motivation 
to carry out rehabilitation with crutches and having good vascular status.
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Total Knee Arthroplasty (TKA):  
 Total Knee Arthroplasty is the only effective means of providing a 
painless and functional knee joint in painful arthritic joints. Knee pain caused by 
arthritis with or without deformity is the primary indication for total knee 
replacement. 
 Contraindications for Total knee arthroplasty include recent or current 
knee sepsis, a remote source of ongoing sepsis, extensor mechanism 
discontinuity secondary to muscular weakness and the presence of well 
functioning knee arthrodesis. 
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AIM OF THE STUDY 
 Osteoarthritis is a clinically heterogenous degenerative condition 
characterized by destruction of articular cartilage, due to uncoupling of balance 
between cartilage degeneration and regeneration. 
 The management of osteoarthritis
15 
has varied from conventional therapy 
with physical education, non steroidal anti inflammatory drugs, intra articular 
glucorticoid injection, intra articular injection of hyaluronan etc. Advanced OA 
in whom aggressive medical management has failed to yield desired results are 
managed by joint replacement arthroplasty. 
Pharmacological treatment of osteoarthritis with NSAIDSs is associated 
with an increased risk of GI disturbances along with an alarming rise in NSAID 
induced multisystem complications. Arthroplasty, though a definite treatment 
is usually reserved for advanced stages of OA. The concomitant post operative 
morbidity, cost issues and the need for technical expertise and revisions has 
precluded Arthroplasty from being a common form of treatment. 
 Autologous chondrocyte transplantation and attempts at cartilage repair 
using mesenchymal stem cells and autologous osteochondral plugs are curently 
in experimental stages. 
The Aim of this study is to evaluate the effectiveness of Platelet Rich 
Plasma
17
 in reducing pain and improving physical function, as Platelet Rich 
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Plasma provides a cocktail of growth factors directly into joint cavity. Platelet 
Rich Plasma is postulated to modify the disease process, unlike other methods 
of nonsurgical treatment which provide symptomatic relief. 
Platelet Rich Plasma is a cost effective tool that could obviate the need for 
Total Joint Arthroplasty, or atleast reduce the number of revision surgeries. 
  
 
 
. 
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      PATHOPHYSIOLOGY OF CARTILAGE CHANGES IN OA 
The Primary change is a defect in collagen network of matrix and 
evidence supports the concept that MMPs account for much of the loss of 
cartilage matrix in OA. 
MMPs, plasmin and cathepsins all appear to be involved in the 
breakdown of articular cartilage in OA.TIMP and PAI- 1 work to stabilize the 
system while growth factors such as insulin like growth factor -1 and 
Transforming growth factor –β are implicated in repair process. 
 Nitric oxide (NO) plays a significant role in articular cartilage damage in 
OA. Nitric oxide stimulates synthesis of MMPs by chondrocytes. Chondrocytes 
are the major source of NO, the synthesis of which is stimulated by IL-1 and 
TNF and by shear stress. 
Recent evidences on the beneficial effects of Platelet Rich Plasma In 
healing chronic conditions
12
 such as lateral epicondylitis and plantar fasciitis has 
kindled interest on the usage of PRP in knee osteoarthritis. 
Platelets play a central role in normal hemostasis. Platelets contain an 
abundance of growth factors and secrete numerous bio active proteins 
responsible for attracting mesenchymal stem cells, osteoblasts thus expediting 
tissue regeneration and healing. 
44 
 
Autologous Platelet rich plasma is a volume of plasma produced by 
centrifuging patient‘s whole blood, yielding a high concentration of platelets 
above baseline levels. Depending on the method of collection, the product may 
contain white blood cells above baseline levels. Platelets and white blood cells 
are sources of high concentration of cytokines. 
Cytokines are well documented to modify processes such as cell 
migration, angiogenesis, and collagen synthesis and wound healing. 
Platelet rich plasma delivers high concentrations of autologous  Growth   
factors
6
 contained in the alpha granules of platelets. Among  these are 
 Transforming Growth Factor-β is involved in phenotype expression, 
differentiation of chondrocytes, matrix deposition and decreasing the 
suppressing effect of IL1 on Proteoglycan synthesis in cartilage. 
  Platelet Derived Growth Factor promotes maintenance of hyaline like 
phenotype, proliferation of chondrocytes and proteoglycan production. 
 Insulin Growth Factor stimulates synthesis of proteoglycan Epidermal 
growth factor promotes differentiation of cells, epithelialisation and aids 
collagenases. 
 Vascular endothelial growth factor promotes angiogenesis. 
  Connective tissue growth factor stimulates vessel permeability and 
endothelial cell mitogenesis. 
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REVIEW OF LITERATURE 
 Patel et al in their study in 2013 compared the efficacy of platelet rich 
plasma in treating osteoarthritis with that of placebo and concluded that Group 
of patients treated with PRP fared better in all assessment parameters. 
 The study also concluded that a single dose of leucocyte filtered platelet 
when administered in concentrations more than ten times the normal amount 
to be as effective as two injections. 
 Khosbin et al in a systematic review with quantitative synthesis in 2013 
concluded that intraarticular PRP injections may have beneficial effects in the 
treatment of adult patients with mild to moderate osteoarthritis. The study also 
reported increased incidence of non specific adverse events among patients 
treated with Platelet rich plasma. 
 Kalbkhani et al in 2014 studied the effect of PRP in experimentally 
induced OA in rabbits knee joint concluded that PRP group had near normal 
joint structure at 16 week post op interval and hence PR could potentially be 
used for the treatment of osteoarthritis. 
 Giuseppe Filardo in 2010 studied about platelet rich plasma intra articular 
knee injections for the treatment of degenerative cartilage lesions and 
osteoarthritis concluded that treatment with PRP injections can reduce pain 
and improve knee function and quality of life with short term efficacy. 
46 
 
 Kon et al Trial - the effectiveness of PRP injections were compared to 
hyaluronic acid (HA) intra-articular injection therapy. The primary outcomes 
of pain reduction and symptoms and function improvements were measured 
through the International Knee Document Committee (IKDC) and Visual 
Analogue Scale (EQ VAS) scoring system. 
 Evaluation of the IKDC score in the PRP group showed a steady increase 
from 41.2 (baseline) to 62.7 and 64.0 at 2 and 6 months follow up, 
respectively. 
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OBJECTIVES 
To evaluate the role of  Autologous Platelet Rich Plasma in the treatment  
of  patients presenting with primary osteoarthritis  and to analyse  whether it 
could be a cost effective disease modifying measure, bereft of major side effects 
and operative costs. 
 
STUDY DESIGN 
 Randomized controlled trial. The patients were subjected to a 
standardized injection protocol and were assessed on variable such as pain, 
stiffness and physical function using WOMAC scale and for pain using visual 
analog scale at pre injection, 6 weeks post injection, 3 months  and 6 months 
post injection.  
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MATERIALS AND METHODS 
 The patients attending the OPD of Orthopaedics Department at Stanley 
Medical College with complaints of bilateral knee pain were screened and those 
diagnosed as bilateral Knee Osteoarthritis were chosen for the study.  
 The Patients, classified either grade 0 to 4 on the Kellgren-Lawrence 
grading scale or grade 1 to 4 on the Ahlback scale,  were included in the study 
after prior well informed written consent. 
Hundred Patients were chosen and randomly divided into two groups of 
fifty each. Group I received intra articular injection Platelet Rich Plasma in to 
both knees served as study group. Group II received normal saline and served as 
control. 
  Randomization ensured that both the groups were comparable with 
respect to age, sex, height, weight, body mass index and pre injection WOMAC 
score. 
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EXCLUSION CRITERIA 
 Immunosuppresed patients 
 Patients with secondary osteoarthritis 
 Patients with connective tissue disorders 
 Patients with inflammatory disorder of joints 
 Patients who have received steroid injections within past 6 months 
 Patients with haemoglobin  less than 10 mg% 
 Patients with tumours, metabolic diseases of bone 
 Patients with coexisting backache 
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KELLGREN LAWRENCE GRADING OF OSTEOARTHRITIS
10
 
Grade 0: no radiographic features of OA are present 
Grade 1: doubtful narrowing of joint space and possible osteophytic 
Lipping 
Grade 2: definite osteophytes, definite narrowing of joint space 
Grade 3: moderate multiple osteophytes, definite narrowing of joints 
space, some sclerosis and possible deformity of bone contour 
Grade 4: large osteophytes, marked narrowing of joint space, severe 
sclerosis and definite deformity of bone contour 
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AHLBACK RADIOLOGICAL CRITERIA
1 
Grade 1: Joint Space Narrowing (Less Than 3 Mm) 
Grade 2: Joint Space Obliteration 
Grade 3: Minor Bone Attrition (0-5 Mm) 
Grade 4: Moderate Bone Attrition (5-10 Mm) 
Grade 5: Severe Bone Attrition (More Than 10 Mm) 
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The Department of Transfusion Medicine at Stanley medical college and 
Government Stanley Hospital had gracefully consented to prepare and provide 
Autologous Platelet Rich Plasma 
7
. 
 About 350 ml of venous blood was collected from the patient.     
The Patient was blinded from knowing the amount of blood collected.  The 
collected blood was centrifuged in a refrigerated centrifuge and Platelet Rich 
Plasma 
11 
was separated after removing red blood cells and buffy coat. The 
whole process of separating Platelet Rich Plasma was standardized and done 
under strict aseptic precautions.  
The process yielded packed cells and fresh frozen plasma which was 
transfused back to the patient. 
The Patients baseline platelet count and leucocyte count were determined 
and Platelet Rich Plasma was quantified as having eight to ten times the 
baseline valve of platelets. The Concentration of Platelets in final product were 
corroborated by the Department of Transfusion Medicine on a periodic basis. 
 We in this study did not use leucocyte filter and the final Platelet Rich 
Plasma  contained minute traces of leucocytes. About 10 ml of blood was 
removed from the control group and was subjected to routine laboratory 
testing. 
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INJECTION PROTOCOL: 
 The Injection procedure was performed in Emergency operation 
theatre. The Patient was placed supine on the operation table. Parts 
painted and draped. Under sterile aseptic precautions 8 ml of Platelet Rich 
Plasma mixed with 2 ml of calcium gluconate  was injected into the supra 
patellar pouch of knee or into the joint cavity from medial approach 
sterile bandaging  given. The Patient is advised bed rest for 2 days. 
 The Patient is advised to avoid NSAIDS for 2 days before and after 
injection. Paracetamol in doses of 500mg is allowed in cases of febrile 
illness or discomfort due to pain. In the control group, 8ml of Normal 
Saline is injected in to the suprapatellar pouch of the patients. 
 The Patients are advised to carry on with their regular routine work 
from Day 2. 
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OUTCOME ANALYSIS: 
 The study group and the control group are advised to follow up at 6 
weeks, 3 months and 6 months .Outcome analysis for the efficacy was 
done for reduction in pain, reduction in stiffness and improvement in 
physical function using WOMAC scale. 
 The Patients were also assessed for reduction in pain using Visual 
analog scale both at pre injection and at 6 months post injection. 
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CASE ILLUSTRATION NO.1 
Abdul majeet presented to the OPD with c/o chronic pain in both knees 
for the past 2 yrs. He had exhausted all conventional mode of therapies. 
The X ray showed clear joint space narrowing of medial compartment  
with marginal osteophytes. He was taken up for Platelet Rich Plasma.   
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CASE ILLUSTRATION 2: 
Valarmathi , 45/F, presented to OPD with c/o chronic knee pain .she was 
diagnosed as having  Kellgren Lawrence grade 3  osteoarthritis in both 
her knees. She was treated by intraarticular Platelet Rich Plasma 
injection.  
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CASE ILLUSTRATION 3: 
Pichamuthu 60/M, presented to the OPD with c/o chronic pain over both 
knees .He was facing difficulty in squatting, climbing stairs. Radiologic 
investigation revealed Kellgren-Lawrence grade 4 osteoarthritis. He was 
treated by intraarticular Platelet Rich Plasma injection.  
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THE WOMAC (WESTERN ONTARIO AND MCMASTER 
UNIVERSITIES) INDEX OF OSTEOARTHRITS
5, 17
 
Overview:  
The WOMAC (Western Ontario and McMaster Universities) index is 
used to assess patients with osteoarthritis of the hip or knee using 24 parameters. 
It can be used to monitor the course of the disease or to determine the 
effectiveness of Therapy 
Scale of difficulty: 0 = None, 1 = Slight, 2 = Moderate, 3 = Very, 4 = 
Extremely 
CIRCLE ONE NUMBER FOR EACH ACTIVITY 
PAIN 
 1. Walking           0 1 2 3 4 
2. Stair Climbing   0 1 2 3 4 
3. Nocturnal          0 1 2 3 4 
4. Rest                   0 1 2 3 4 
5. Weight bearing 0 1 2 3 4 
STIFFNESS  
1. Morning stiffness   0 1 2 3 4 
2. Stiffness occurring later in the day 0 1 2 3 4 
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PHYSICAL FUNCTION  
1. Descending stairs 0 1 2 3 4 
2. Ascending stairs 0 1 2 3 4 
3. Rising from sitting 0 1 2 3 4 
4. Standing 0 1 2 3 4 
5. Bending to floor 0 1 2 3 4 
6. Walking on flat surface 0 1 2 3 4 
7. Getting in / out of car 0 1 2 3 4 
8. Going shopping 0 1 2 3 4 
9. Putting on socks 0 1 2 3 4 
10. Lying in bed 0 1 2 3 4 
11. Taking off socks 0 1 2 3 4 
12. Rising from bed 0 1 2 3 4 
13. Getting in/out of bath 0 1 2 3 4 
14. Sitting 0 1 2 3 4 
15. Getting on/off toilet 0 1 2 3 4 
16. Heavy domestic duties 0 1 2 3 4 
17. Light domestic duties 0 1 2 3 4. 
Total Score: ______ / 96 = _______% 
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VISUAL ANALOG SCALE FOR PAIN 
The Pain, the Patient perceive is graded on a visual scale and the score 
calculated.  
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STATISTICAL ANALYSIS 
Age Distribution 
 
 
Age Distribution 
Platelet 
Rich 
Plasma 
% 
Normal 
Saline 
% 
≤ 40 years 7 14.00 0 0.00 
41-50 years 19 38.00 17 34.00 
51-60 years 19 38.00 26 52.00 
> 60 years 5 10.00 7 14.00 
Total 50 100 50 100 
 
Age Distribution 
Platelet Rich 
Plasma 
Normal Saline 
N 50 50 
Mean 49.92 54.16 
SD 7.72 5.36 
P value Unpaired t Test                                       0.1120 
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  Gender Distribution 
 
 
 
Gender 
Distribution 
Platelet 
Rich 
Plasma 
% 
Normal 
Saline 
% 
Male 40 80.00 41 82.00 
Female 10 20.00 9 18.00 
Total 50 100 50 100 
P values Chi Squared Test                             0.0833 
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Height Distribution 
 
 
Height 
Distribution 
Platelet 
Rich 
Plasma 
% 
Normal 
Saline 
% 
≤ 150 cms 4 8.00 9 18.00 
151-160 cms 27 54.00 18 36.00 
161-170 cms 17 34.00 17 34.00 
170-180 cms 2 4.00 6 12.00 
Total 50 100 50 100 
 
 
Height Distribution 
Platelet Rich 
Plasma 
Normal Saline 
N 50 50 
Mean 159.66 159.68 
SD 6.63 8.39 
P value Unpaired t Test                                     0.9895 
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Weight Distribution 
 
 
Weight 
Distribution 
Platelet 
Rich 
Plasma 
% 
Normal 
Saline 
% 
≤ 60  kgs 6 12.00 9 18.00 
61-70 kgs 27 54.00 27 54.00 
71-80 kgs 13 26.00 12 24.00 
81-90 kgs 4 8.00 2 4.00 
Total 50 100 50 100 
 
 
Weight Distribution 
Platelet Rich 
Plasma 
Normal Saline 
N 50 50 
Mean 68.62 67.66 
SD 6.84 6.63 
P value Unpaired t Test                                    0.4777 
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BMI Distribution 
 
 
BMI Distribution 
Platelet 
Rich 
Plasma 
% 
Normal 
Saline 
% 
Underweight (≤ 18.49) 0 0.00 0 0.00 
Normal (18.50 to 24.99) 11 22.00 15 30.00 
Overweight (25 to 29.99) 33 66.00 29 58.00 
Obese 6 12.00 6 12.00 
Total 50 100 50 100 
 
 
BMI Distribution 
Platelet Rich 
Plasma 
Normal Saline 
N 50 50 
Mean 26.97 26.64 
SD 2.70 2.92 
P value Unpaired t Test                                    0.5507 
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WOMAC Score 
 
 
WOMAC Score 
Preinjectio
n 
6 
weeks 
3 
month
s 
6 
month
s 
Platelet Rich 
Plasma 
N 50 50 50 50 
Mean 74.20 62.46 47.68 33.40 
SD 4.85 6.60 8.15 7.59 
Normal Saline 
N 50 50 50 50 
Mean 69.80 64.10 62.46 66.44 
SD 4.68 5.50 5.44 5.01 
P value Unpaired t Test 0.1804 0.0000 0.0000 0.0000 
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Pain Score 
 
 
Pain Score Preinjection 
6 
weeks 
3 
months 
6 
months 
Platelet Rich 
Plasma 
N 50 50 50 50 
Mean 16.58 11.32 7.44 5.34 
SD 3.08 2.76 1.93 1.42 
Normal Saline 
N 50 50 50 50 
Mean 16.30 13.74 13.66 15.46 
SD 2.39 2.28 2.35 1.94 
P value Unpaired t Test 0.6132 0.0000 0.0000 0.0000 
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Stiffness Score 
 
 
Stiffness Score Preinjection 
6 
weeks 
3 
months 
6 
months 
Platelet Rich 
Plasma 
N 50 50 50 50 
Mean 5.50 4.60 3.78 3.40 
SD 1.22 1.20 1.09 1.14 
Normal Saline 
N 50 50 50 50 
Mean 5.16 4.56 4.46 4.78 
SD 0.93 0.81 0.73 0.84 
P value Unpaired t Test 0.1204 0.8453 0.0004 0.0000 
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Physical Function Score 
 
 
Physical Function Score Preinjection 
6 
weeks 
3 
months 
6 
months 
Platelet Rich 
Plasma 
N 50 50 50 50 
Mean 52.12 46.54 36.46 24.62 
SD 3.77 4.53 6.49 6.33 
Normal 
Saline 
N 50 50 50 50 
Mean 48.30 45.80 44.38 46.20 
SD 3.17 3.91 3.88 3.67 
P value Unpaired t Test 0.3840 0.0000 0.0000 0.0000 
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Visual Analog Score 
 
 
Visual Analog Score Preinjection Postinjection 
Platelet Rich 
Plasma 
N 50 50 
Mean 7.22 3.06 
SD 0.97 1.24 
Normal Saline 
N 50 50 
Mean 6.86 4.98 
SD 0.81 0.89 
P value Unpaired t Test 0.0473 0.0000 
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 DISCUSSION 
 Osteoarthritis is a disorder of synovial joints characterized by focal loss of 
hyaline cartilage with proliferation of new bone and remodeling of joint 
contour, mainly due to uncoupling of balance between cartilage regeneration 
and degeneration. Osteoarthritis is a dynamic repair process of synovial joints 
that may be triggered a variety of insults. 
 We in our study had randomly chosen 100 patients with classic findings 
of Osteoarthritis and divided them in to two groups. Both the groups were 
comparable on baseline characteristics of age, height, weight, BMI,                 
pre injection WOMAC score. Fifty of these patients were administered an intra 
articular injection of Platelet Rich Plasma and other fifty received Normal 
Saline. 
The Efficacy of Platelet Rich Plasma in reducing pain ,stiffness and 
physical function were assessed and scored on WOMAC index for both study 
and control group. The Results were analysed using unpaired t-test and chi-
square test. 
 Age distribution revealed mean age in group I to be 49.92 and the mean 
age in Group II was 54.16.The p-value derived using unpaired t-test is 0.1120, 
rendering age factor insignificant. 
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 Gender distributions were comparable on both groups with 80 % being 
male 20% being female. The p-valve using chi square test is 0.0833 .The 
Gender factor was insignificant. 
 The mean height in group I was 159.66 and the mean height in Group II 
was 159.68.The p-valve using unpaired t test turned insignificant (0.9895). 
 The mean weight, in group I was 68.62 and group II was 67.66 with p-
valve of 0.4777(insignificant). 
 The mean BMI was 26.97 in group I and 26.64 in Group II. The p-valve 
is 0.5507(insignificant). 
 Thus the study ensured that all patients were comparable on baseline 
characters. 
 The Global WOMAC showed a mean of 74.2 at pre injection period 
which decreased to 62.46 at 6 weeks follow up and 47.68 at 3 months and 
declining to 33.40 at 6 months.  
 The study showed a significant decrease in global WOMAC score, which 
was also consistent throughout the study period. 
 The Individual variables such as pain, stiffness and physical function 
were assessed. Mean score for pain showed a decrease from 16.58 to 11.32 at 6 
weeks post injection .At the end of 6 months follow up, the mean was 5.34. 
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 The mean score for pain in group II showed a marginal decreased from 
16.30 to 13.74 at 6 weeks but returned to 15.46 at 6 months follow up. 
 The p-value using unpaired t-test showed significant improvement. 
Secondary variable stiffness showed significance difference at 3 months follow 
up and 6 months follow up. 
 The mean of Physical function   decreased from a pre injection score of 
52.12 to 24.62 at 6 months follow up in Group I. 
 Group II showed a marginal dip in mean scores from 48.30 to 45.80 and 
to 44.38 at 3 months .The scores leveled at 46.20 at the end of 6 months  
Visual analog score showed a decrease in mean of 7.22 to 3.06 which 
denoted a change of patient‘s perception of pain from intense, dreadful, horrible 
pain to mild annoying pain in Group I. 
 Group II showed a marginal dip from 6.86 to 4. 98 on mean, showing 
insignificant change in pain. 
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CONCLUSION 
 The Epidemic of Modernization coupled with effective health care 
delivery has led to an expanded lifespan of human beings. The focus of health 
care providers is undergoing a drift towards non communicable and 
degenerative disorders. 
 Osteoarthritis represents a failure of diarthrodial joint, characterized by 
degenerative changes in articular cartilage of joint. The management of 
Osteoarthritis has undergone a sea change during the last century. Osteoarthritis 
has been managed by conservative methods like lifestyle changes, 
physiotherapy and surgical methods like joint replacement arthroplasty, 
depending upon the stage of the disorder. 
 A constant search for molecules that could aid in cartilage regeneration, 
thus interfering in disease process has thrown up surprises. One such ideology 
is, garnering the beneficial effect of growth factors in platelets to regenerate 
cartilage in a synovial joint. 
 Our study relied on injecting a highly concentrated mix of platelets into 
joint cavity and observing the patients for reduction in symptoms of pain, 
stiffness and improvement in physical function .our study has revealed a 
consistent reduction in pain and stiffness and a clear improvement in lifestyle of 
the patients. 
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 Our study has thrown up an interesting choice of treatment modality using 
Platelet Rich Plasma in the treatment of Knee Osteoarthritis and it has proved 
efficacious in the observation period of six months. 
COMPLICATIONS: 
There were no major complications or incidences of infection in our study group 
and control group. 
LIMITATIONS: 
 Long term follow up needed with M.R.I to assess the regeneration of 
cartilage. 
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MASTER CHART  
GROUP-I PLATELET RICH PLASMA 
S.NO NAME AGE SEX HEIGHT WEIGHT BMI PREINJECTION 
SCORE 
WOMAC 
SCORE--
6 
WEEKS 
WOMAC 
SCORE -3 
MONTHS 
WOMAC 
SCORE-6 
MONTHS 
VAS 
PRE 
INJECTION 
VAS 
POST 
INJECTION 
1.  PERIYASAMY 52 M 160 65 25.4 82 72 66 52 8 4 
2.  FATHIMA 56 F 152 69 29.9 86 80 72 66 8 5 
3.  ARUMUGHAM 58 M 156 70 28.8 78 70 62 50 6 2 
4.  MANIKANDAN 40 M 164 65 24.2 74 66 48 30 6 2 
5.  ARUMUGHAM 38 M 160 64 25 72 60 30 24 6 2 
6.  LOGANATHAN 56 M 148 62 28.3 70 60 44 30 6 2 
7.  MUSTAFA 52 M 156 64 26.3 78 64 42 32 8 4 
8.  YUSUF 46 M 152 63 27.3 74 52 32 26 6 2 
9.  VALARMATHY 45 F 150 58 25.8 72 66 46 28 8 2 
10.  SHANMUGHAM 48 M 160 78 30.5 68 56 44 38 6 5 
11.  MOHAN 48 M 175 76 24.8 66 52 46 28 6 2 
12.  SURESH 45 M 168 64 22.7 66 52 44 32 6 4 
13.  PARTHASARATHY 60 M 162 70 26.7 74 52 40 36 6 2 
14.  ABDUL GAFFER 58 M 152 63 27.3 68 56 42 32 6 2 
15.  JEYAKUMAR 42 M 160 68 26.6 68 52 38 28 6 2 
16.  STELLAMARY 38 F 145 62 29.5 68 56 40 36 6 2 
17.  ESTHAR 48 F 142 66 32.7 66 46 40 32 6 3 
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18.  PERIYASAMY 62 M 160 78 30.5 78 66 52 40 6 2 
19.  NAGAVATHY 56 F 156 56    23 78 66 54 30 8 2 
20.  VENKATESAN 56 M 164 66 24.5 72 66 52 40 6 4 
21.  MOHAN 48 M 160 68 26.6 70 66 52 32 8 2 
22.  GOVINDARAJ 45 M 158 68 27.2 72 62 54 38 6 2 
23.  RASUL 48 M 162 72 27.4 74 58 40 26 8 2 
24.  CHANDRASEKAR 56 M 170 75 26 68 56 38 24 8 3 
25.  SUBAA 48 F 156 66 27.1 78 62 42 30 8 5 
26.  ANWAR 44 M 160 68 26.6 76 66 52 30 6 3 
27.  SANTHANAM 52 M 170 74 25.6 74 66 54 40 8 6 
28.  ANNAMALAI 62 M 163 58 21.8 68 54 40 30 6 2 
29.  KARTHIK 48 M 160 69 27 72 66 44 32 8 5 
30.  MD.ASIF 56 M 162 78 29.7 70 62 50 40 8 5 
31.  JAYA 52 F 156 70 28.8 72 62 46 28 8 4 
32.  ANNAMMA 48 F 160 68 26.6 76 64 38 26 8 1 
33.  SIVA 56 M 158 68 27.2 70 66 52 38 8 4 
34.  ARUL 63 M 163 61    23 72 66 54 36 8 3 
35.  SHANMUGHAM 55 M 162 71 27.1 78 66 45 32 8 2 
36.  KUMAR 53 M 167 82 29.4 78 68 52 32 6 3 
37.  BOOPATHI 46 M 153 72 30.8 72 68 58 30 8 3 
38.  VIJAYA 45 F 158 60 24 78 62 42 28 8 3 
39.  VENKATESHWARULU 42 M 165 72 26.4 76 60 44 30 8 3 
40.  JOTHI 38 F 160 58 22.7 74 58 44 28 7 3 
41.  SOLOMON DOSS 53 M 157 81 32.9 78 66 52 40 8 5 
42.  RAVI 35 M 163 71 26.7 74 66 48 32 8 4 
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43.  JAYARAMAN 41 M 156 67 27.5 82 68 56 40 8 6 
44.  SASIKUMAR 38 M 169 73 25.6 76 66 48 26 8 2 
45.  PERUMAL 42 M 173 82 27.4 84 70 58 32 8 3 
46.  VENKATESAN 38 M 168 69 24.4 74 52 40 26 8 2 
47.  UMAKANTH 58 M 157 86 34.9 78 65 49 28 8 3 
48.  PERUMAL 61 M 163 73 27.5 82 66 52 38 8 4 
49.  THIRUNAVUKARASU 59 M 154 59 24.9 80 72 58 36 8 3 
50.  SUBBAIAH 62 M 158 65 26 76 64 48 32 8 2 
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GROUP II- NORMAL SALINE 
S.NO NAME AGE SEX HEIGHT WEIGHT BMI PREINJECTION 
SCORE 
WOMAC 
SCORE--
6 WEEKS 
WOMAC 
SCORE -3 
MONTHS 
WOMAC 
SCORE-6 
MONTHS 
VAS 
PRE 
INJECTION 
VAS 
POST 
INJECTION 
51. KUMAR 48 M 165 69 25.34 68 60 66 68 8 7 
52. KALAIARASI 55 F 163 58 21.83 72 68 66 68 7 5 
53. SAROJA 61 F 158 62 24.84 74 65 62 70 8 6 
  54. MARKANDAN 62 M 160 69 26.95 72 70 68 74 6 4 
55. EASWARAN 48 M 172 74 25.01 72 70 68 68 8 5 
56. THANGADURAI 46 M 178 73 23.04 68 60 60 62 7 4 
57. SELLAPANDIAN 60 M 167 69 24.74 72 70 70 70 7 5 
58. RAJA 58 M 159 70 27.69 68 58 56 62 6 4 
59. GUNA  49 M 163 68 25.59 66 66 58 58 6 5 
60. SHANMUGHAM 53 M 164 68 25.28 66 52 58 60 7 5 
61. ANBU 59 M 172 68 22.99 74 62 62 68 8 6 
62. KANNAN 49 M 165 63 23.14 66 58 56 66 6 6 
63. DHIVYA 53 F 167 59 21.16 64 54 52 60 7 5 
64. DHANABAKIYAM 63 F 156 68 27.94 73 62 69 75 6 4 
65. DHANASEKARAN 57 M 147 56 25.92 66 68 60 60 6 4 
66. ABDUL SHERIFF 59 M 159 79 31.25 72 62 60 66 8 6 
67. KALAIMATHI 54 F 163 65 24.46 68 62 58 60 7 5 
68. HARI 49 M 158 68 27.24 70 69 63 66 6 4 
69. MD.ASIF 61 M 163 72 27.1 72 60 65 70 7 4 
70. FATHIMA 53 F 153 68 29.05 69 59 58 70 6 4 
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71. BABI 49 M 143 64 31.3 76 70 64 70 7 5 
72. THYAGU 63 M 173 81 27.06 78 68 66 70 8 4 
73. GANAPATHY 49 M 165 67 24.61 68 60 58 60 7 4 
74. YOGI 58 M 159 73 28.88 73 73 68 68 8 5 
75. SATHISH 52 M 156  68 27.94 69 64 58 60 6 5 
76. RAHAMATHULLA 59 M 166 72 26.13 74 68 63 69 8 6 
77. KAMALUDEEN 49 M 171 83 28.38 76 69 69 70 8 6 
78. CHINNATHAMBI 53 M 158 59 23.63 62 57 54 58 7 4 
79. ELUMALAI 48 M 148 57 26.02 65 66 60 58 6 4 
80. MANOHARAN 54 M 158 63 25.24 67 64 60 62 6 5 
81. KUMAR 55 M 172 69 23.32 70 68 63 66 7 6 
82. DEVA 59 M 164 79 29.37 68 66 66 66 6 4 
83. KRISHNAN 63 M 156 58 23.83 69 67 60 62 7 6 
84. BOOMINATHAN 56 M 165 63 23.14 70 64 65 70 6 5 
85. MARIMUTHU 49 M 147 59 27.3 68 63 60 68 7 6 
86. ELAVARASAN 56 M 146 63 29.56 56 48 48 56 6 4 
87. ARUMUGHAM 57 M 159 76 30.06 68 58 56 70 6  5 
88. PONNIAH 53 M 165 68 24.98 66 60 58 68 6 5 
89. KAMARAJ 46 M 158 67 26.84 72 66 62 68 8 7 
90. NAGOOR KANI 57 M 164 63 23.42 80 72 72 78 8 6 
91. CHANDRAN 56 M 145 69 32.82 78 72 72 72 7 6 
92. HANUMANTH 48 M 152 79 34.19 76 70 70 70 6 5 
93. SOLAI 58 M 167 75 26.89 72 70 70 70 7 4 
94. KANTHA 49 F 147 59 27.3 68 66 68 70 6 4 
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95. KUMAR 44 M 142 68 33.72 58 58 58 58 6 5 
96. SANKU 45 M 159 68 26.9 67 65      66 68 7 4 
97. ARUNA 49 F 149 58 26.12 68 60 58 68 6 4 
98. KRISHNAN 56 M 158 63 25.24 74 68 66 70 8 6 
99. AMEEN 62 M 157 71 28.8 68 60 60 68 7 5 
100. JEYAM 59 F      163      75        28.23 74 70 70 70 8 6 
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WOMAC SCORE DETAILED- GROUP I 
s.no Name Preinjection score 6 weeks 3 months 6 months 
  pain stiffness Physical 
function 
pain stiffness Physical 
function 
pain stiffness Physical 
function 
pain stiffness Physical 
function 
1 PERIYASAMY 18 8 56 14 6 52 12 4 50 8 4 40 
2 FATHIMA 18 8 60 15 8 57 15 6 51 12 6 48 
3 ARUMUGHAM 15 6 57 11 6 53 7 6 49 6 6 38 
4 MANIKANDAN 20 6 48 16 4 46 10 2 36 6 2 22 
5 ARUMUGHAM 18 4 50 12 4 44 5 2 23 4 2 18 
6 LOGANATHAN 18 6 46 13 6 41 8 5 31 6 4 20 
7 MUSTAFA 16 8 54 10 6 48 6 6 30 4 6 22 
8 YUSUF 17 6 51 7 4 41 6 4 22 4 4 16 
9 VALARMATHY 18 8 46 15 6 45 7 4 35 6 4 18 
10 SHANMUGHAM 14 6 48 10 4 42 6 2 36 6 2 30 
11 MOHAN 12 4 50 8 4 40 8 4 34 4 4 20 
12 SURESH 12 4 50 8 4 40 6 4 34 4 4 24 
13 PARTHASARATHY 15 4 55 8 4 40 7 3 30 4 3 29 
14 ABDUL GAFFER 13 3 52 9 3 44 5 2 35 5 2 25 
15 JEYAKUMAR 13 3 52 8 2 42 7 2 29 6 2 20 
16 STELLAMARY 10 4 54 7 3 46 5 2 33 5 2 29 
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17 ESTHAR 8 4 54 4 2 40 4 2 34 4 2 26 
18 PERIYASAMY 17 5 56 12 3 51 7 3 42 5 3 32 
19 NAGAVATHY 22 6 50 12 6 48 8 5 41 6 3 21 
20 VENKATESAN 16 5 51 12 4 50 8 4 40 6 2 32 
21 MOHAN 12 4 54 9 3 54 5 3 44 4 2 26 
22 GOVINDARAJ 14 6 52 9 6 47 8 6 40 6 6 26 
23 RASUL 15 5 54 10 4 44 6 4 30 5 3 18 
24 CHANDRASEKAR 17 6 45 12 5 39 7 4 27 5 2 17 
25 SUBAA 20 6 52 12 4 46 7 4 31 5 4 21 
26 ANWAR 19 6 51 14 6 46 10 4 38 6 4 20 
27 SANTHANAM 15 7 52 11 6 49 8 5 41 6 3 31 
28 ANNAMALAI 16 5 47 10 4 40 8 4 28 6 3 21 
29 KARTHIK 22 5 45 18 4 44 9 3 32 6 3 23 
30 MD.ASIF 20 6 44 14 6 42 7 5 38 5 5 30 
31 JAYA 19 7 46 14 6 42 8 4 34 6 4 18 
32 ANNAMMA 17 6 53 12 4 48 6 4 28 4 2 20 
33 SIVA 16 6 48 12 6 48 8 4 40 7 4 27 
34 ARUL 17 5 50 14 4 48 10 4 40 8 4 24 
35 SHANMUGHAM 18 6 54 12 5 49 7 3 35 5 3 24 
36 KUMAR 15 5 58 10 5 53 7 3 42 5 3 24 
37 BOOPATHI 14 6 52 12 5 51 8 4 46 4 3 23 
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38 VIJAYA 18 6 54 10 5 47 6 3 33 4 3 21 
39 VENKATESHWARULU 20 5 51 12 4 44 7 4 33 6 4 20 
40 JOTHI 19 5 50 13 4 41 8 3 33 6 3 19 
41 SOLOMON DOSS 16 6 56 10 5 51 6 5 41 4 5 31 
42 RAVI 13 5 56 9 5 52 6 3 39 4 2 26 
43 JAYARAMAN 21 6 55 12 5 51 9 4 43 6 4 30 
44 SASIKUMAR 17 4 55 10 4 52 8 4 36 4 4 18 
45 PERUMAL 22 6 56 15 5 50 9 4 45 4 3 25 
46 VENKATESAN 14 5 55 7 3 42 5 3 32 4 3 19 
47 UMAKANTH 18 7 53 13 5 47 7 5 37 5 4 19 
48 PERUMAL 19 5 58 13 4 49 9 4 39 5 4 29 
49 THIRUNAVUKARASU 20 6 54 16 5 51 10 3 45 6 3 27 
50 SUBBAIAH 16 4 56 10 4 50 6 4 38 5 3 24 
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WOMAC SCORE –GROUP II –NORMAL SALINE 
s.no Name PREINJECTION 
SCORE 
6 WEEKS 3 MONTHS 6 MONTHS 
  pain stiffness Physical 
function 
pain stiffness Physical 
function 
pain stiffness Physical 
function 
pain stiffness Physical 
function 
1. KUMAR 16 6 46 13 4 43 16 4 46 14 4 50 
2. KALAIARASI 18 6 48 16 6 46 17 4 45 17 5 46 
3. SAROJA 20 6 48 15 4 46 15 5 42 20 5 45 
4. MARKANDAN 15 6 51 14 6 50 16 5 47 19 6 49 
5. EASWARAN 15 5 52 13 5 52 15 4 51 13 5 50 
6 THANGADURAI 16 6 46 12 6 42 12 6 42 14 6 42 
7. SELLAPANDIAN 18 6 48 16 6 48 16 6 48 16 6 48 
8. RAJA 18 4 46 13 3 42 13 3 40 16 4 42 
9. GUNA 17 4 45 17 4 45 14 4 40 14 4 40 
10. SHANMUGHAM 15 4 47 10 4 38 14 4 40 14 4 42 
11. ANBU 15 6 53 13 4 45 13 4 45 15 6 47 
12. KANNAN 17 4 45 13 4 41 13 4 39 18 4 44 
13. DHIVYA 17 4 43 12 4 38 12 4 36 14 4 42 
14. DHANABAKIYAM 18 5 50 12 4 46 16 4 49 16 4 55 
15. DHANASEKARAN 14 6 46 14 6 48 12 4 44 12 4 44 
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16. ABDUL SHERIFF 13 6 53 10 4 48 10 4 46 14 4 48 
17. KALAIMATHI 18 4 46 14 4 44 14 4 40 14 4 42 
18.           HARI 16 6 48 15 6 48 12 6 45 15 6 45 
19. MD.ASIF 13 6 53 10 4 46 13 6 46 15 6 49 
20. FATHIMA 14 4 51 10 4 45 10 4 44 14 6 50 
21. BABI 20 6 50 14 6 50 12 4 48 14 6 50 
22. THYAGU 19 6 51 15 4 49 15 4 47 15 5 50 
23. GANAPATHY 16 6 46 12 5 43 12 5 41 14 5 41 
24. YOGI 18 5 50 18 5 50 15 5 48 15 5 48 
25. SATHISH 14 4 51 12 4 48 10 4 44 12 4 44 
26. RAHAMATHULLA 15 6 53 11 5 52 11 5 47 16 6 47 
27. KAMALUDEEN 17 6 53 15 5 49 15 5 49 16 5 49 
28. CHINNATHAMBI 14 4 44 13 3 41 10 3 41 14 3 41 
29. ELUMALAI 15 5 45 15 5 46 15 5 40 14 4 40 
30. MANOHARAN 17 5 45 15 5 44 15 5 40 16 5 41 
31. KUMAR 20 5 45 18 5 45 13 5 45 16 5 45 
32. DEVA 19 5 44 17 5 44 17 5 44 17 5 44 
33. KRISHNAN 14 4 51 14 4 49 12 4 44 14 4 44 
34. BOOMINATHAN 15 4 51 13 4 47 14 4 47 15 4 51 
35. MARIMUTHU 16 6 46 13 4 46 13 4 43 16 4 48 
36. ELAVARASAN 12 4 40 12 4 32 12 4 32 14 4 38 
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37. ARUMUGHAM 13 5 50 11 4 43 9 4 43 18 4 48 
38. PONNAIAH 16 4 46 10 4 46 10 4 44 16 4 48 
39. KAMARAJ 19 5 48 15 5 46 13 4 45 15 5 48 
40. NAGOORKANI 22 7 51 20 5 47 20 5 47 22 6 50 
41. CHANDRAN 20 7 51 16 5 51 16 5 51 16 6 50 
42. HANUMANTH 18 6 52 16 6 48 16 6 48 16 6 48 
43. SOLAI 19 5 48 15 5 50 17 5 48 17 5 48 
44. KANTHA 13 5 50 11 5 50 13 5 50 15 5 50 
45. KUMAR 12 4 42 12 4 42 12 4 42 12 4 42 
46. SANKU 14 4 49 15 4 46 18 5 43 18 5 45 
47. ARUNA 16 4 48 14 4 42 12 4 42 17 5 46 
48. KRISHNAN 18 6 50 14 4 50 14 4 48 16 4 50 
49. AMEEN 13 5 50 13 4 43 13 4 43 17 5 46 
50. JEYAM 18 6 50 16 4 50 16 4 50 16 4 50 
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PROFORMA 
 
S.No :  
Patient name :  
Age/Sex :                                                              IP No:  
Occupation :  
Address :  
Phone no :       Date of Admission: 
 
-----------------------------------------------------------------------------------------  
Presenting complaints: 
History of Presenting illness 
Past History 
Occupational History: 
Family History: 
General Examination: 
Regional Examination: 
Provisional Diagnosis: 
Radiologic Examination: 
Final Diagnosis: 
Interventional Procedure: Platelet Rich Plasma injection: 
Outcome Analysis WOMAC score:    
Visual analog score: 
 
